Key facts
- BioLattice’s last known valuation is $5.6M (Mar 2026).
- It has raised $1.4M; the latest was Seed Round ($570K) in Mar 2026.
- Notable investors include US National Science Foundation, SOSV, IndieBio, HiveBio, The Enterprise Center Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for BioLattice
- ·The full record, as it builds
Funding rounds
No funding rounds for BioLattice are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioLattice
Developer of a tissue-engineered cornea technology designed to provide a viable alternative to donor tissue for full-thickness transplants. The company's technology offers a corneal prototype with vision-correcting capabilities, enabling patients in need of corneal transplants to regain sight.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2014
- Website
- biolatticetech.com/
- Ownership
- Privately Held (backing)
BioLattice doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioLattice shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioLattice in its N-PORT filings yet. We sweep new filings monthly.